Agilent, Molecular Discovery Reach Co-marketing Deal for Metabolite Identification | GenomeWeb

NEW YORK (GenomeWeb News) – Agilent Technologies and Molecular Discovery on Sunday announced a co-marketing agreement to provide an advanced metabolite identification platform to biopharmaceutical researchers.

Under the terms of the deal, Agilent's high-resolution liquid chromatography/mass spectrometry technology will be co-marketed with Molecular Discovery's Mass-MetaSite software "to enable superior identification and analysis of complex biological mixtures," the firms said in a joint statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.